✦ LIBER ✦

Prednisone is effective as a maintenance therapy in patients with multiple myeloma

Book ID: 120862296
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2002
Weight: 151 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200213450-00026

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A611 Lenalidomide Maintenance Therapy in

A611 Lenalidomide Maintenance Therapy in Patients with Multiple Myeloma

✍ Fillitz, M; Seebacher, A; Reisner, R; Pittermann-Hocker, E 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 81 KB

Continuous low-dose cyclophosphamide–pre

Continuous low-dose cyclophosphamide–prednisone is effective and well tolerated in patients with advanced multiple myeloma

✍ Okke de Weerdt; Niels W.C.J van de Donk; Gerda Veth; Andries C Bloem; Anton Hage 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 97 KB

Bortezomib, melphalan, and prednisone ve

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

✍ María-Victoria Mateos; Albert Oriol; Joaquín Martínez-López; Norma Gutiérrez; An 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 255 KB

Pegylated liposomal doxorubicin, melphal

Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma

✍ R García-Sanz; JM Hernández; A Sureda; J García-Laraña; F Prósper; A Alegre; A B 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB

## Abstract Melphalan & Prednisone (MP) is considered as the standard therapy for Multiple Myeloma (MM) patients not eligible for high‐dose therapy. Here, we report the results of a phase I–II study to evaluate the feasibility and efficacy of the association of PLD to the conventional MP regimen du

Maintenance therapy with bortezomib plus

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

✍ Mateos, M.-V.; Oriol, A.; Martinez-Lopez, J.; Gutierrez, N.; Teruel, A.-I.; Lope 📂 Article 📅 2012 🏛 American Society of Hematology 🌐 English ⚖ 269 KB

A randomised comparison of melphalan wit

A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7

✍ Chaim Shustik; Andrew Belch; Sue Robinson; Sheldon H. Rubin; Sean P. Dolan; Mich 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 760 KB